Your browser doesn't support javascript.
loading
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah, Neeta; Conley, Anthony P; Parra, Edwin Roger; Lin, Heather; Amini, Behrang; Solis Soto, Luisa; Salazar, Ruth; Barreto, Carmelia; Chen, Honglei; Gite, Swati; Haymaker, Cara; Nassif, Elise F; Bernatchez, Chantale; Mitra, Akash; Livingston, John Andrew; Ravi, Vinod; Araujo, Dejka M; Benjamin, Robert; Patel, Shreyaskumar; Zarzour, Maria A; Sabir, Sharjeel; Lazar, Alexander J; Wang, Wei-Lien; Daw, Najat C; Zhou, Xiao; Roland, Christina L; Cooper, Zachary A; Rodriguez-Canales, Jaime; Futreal, Andrew; Soria, Jean-Charles; Wistuba, Ignacio I; Hwu, Patrick.
Afiliação
  • Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: nsomaiah@mdanderson.org.
  • Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Amini B; Department of Musculoskeletal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Solis Soto L; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Salazar R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Barreto C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gite S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nassif EF; Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mitra A; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Araujo DM; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Benjamin R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sabir S; Department of General Interventional Radiology, Scripps Mercy Hospital, San Diego, CA, USA.
  • Lazar AJ; Department of Pathology, Division of Pathology-Lab Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang WL; Department of Pathology, Division of Pathology-Lab Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Daw NC; Department of Pediatrics, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou X; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Roland CL; Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cooper ZA; Oncology Research & Development, AstraZeneca, Gaithersburg, MD, USA.
  • Rodriguez-Canales J; Oncology Research & Development, AstraZeneca, Gaithersburg, MD, USA.
  • Futreal A; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Soria JC; General Director, Gustave Roussy, Paris-Saclay University, Villejuif, France.
  • Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Moffitt Cancer Center, Tampa, FL, USA.
Lancet Oncol ; 23(9): 1156-1166, 2022 09.
Article em En | MEDLINE | ID: mdl-35934010
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Neoplasias de Tecidos Moles / Neoplasias Ósseas / Osteossarcoma / Sarcoma Alveolar de Partes Moles / Colite Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Neoplasias de Tecidos Moles / Neoplasias Ósseas / Osteossarcoma / Sarcoma Alveolar de Partes Moles / Colite Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article